Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 5.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 1.93 | - |
NAV | ₹36.24 | - |
Fund Started | 25 Jun 2018 | - |
Fund Size | ₹4917.81 Cr | - |
Exit Load | Exit load of 1% if redeemed within 15 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 21.46% | - |
3 Year | 22.63% | - |
5 Year | 26.76% | - |
1 Year
3 Year
5 Year
Equity | 98.07% | - |
Cash | 1.93% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.83% |
Cipla Ltd. | 9.28% |
Dr. Reddy's Laboratories Ltd. | 8.93% |
Divi's Laboratories Ltd. | 5.56% |
Aurobindo Pharma Ltd. | 5.05% |
Lupin Ltd. | 4.67% |
Alkem Laboratories Ltd. | 3.98% |
Gland Pharma Ltd. | 3.73% |
Mankind Pharma Ltd. | 3.22% |
Zydus Lifesciences Ltd. | 2.96% |
Name | Dharmesh Kakkad | - |
Start Date | 23 Feb 2021 | - |
Name
Start Date
Description | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. | - |
Launch Date | 25 Jun 2018 | - |
Description
Launch Date